Acute Lymphocytic Leukemia Therapeutics Market Analysis By Therapy (Chemotherapy, Hyper-CVAD, Linker Regimen, Targeted Therapy, Radiation Therapy), And Segment Forecasts, 2018 - 2025

Industry Insights

The global acute lymphocytic leukemia therapeutics market size was valued at USD 1.5 billion in 2016 and is expected to grow at a CAGR of 10.0%. Rise in incidence of Acute Lymphoblastic Leukemia (ALL) and increase in initiatives undertaken by public and private organizations are some of the key factors expected to drive market growth.

Technological advancements made for detecting affected cells are also considered as one of the drivers for market growth. For instance, Chimeric Antigen Receptor (CAR)-T cell therapy by Novartis AG is a novel therapy. This therapy is in phase II of clinical trials and is estimated to receive FDA approval by 2020.

Various government and nongovernment organizations, such as the American Cancer Society, National Cancer Institute (NCI), and the Foundation for the National Institutes of Health, have undertaken initiatives and arranged diagnostic campaigns for detection of ALL.

Furthermore, the “Therapeutically Applicable Research to Generate Effective Treatments (TARGET)” initiative and “Childhood Cancer Targeted Therapeutics Workshop” have launched many programs and collaborated with many research groups across different countries such as St. Jude Children’s Research Hospital and University of New Mexico etc., to provide facilities to patients for early diagnosis and better treatment of leukemia.

According to the American Cancer Society, in 2017, around 2,620 women & 3,350 men are expected to be diagnosed with ALL and around 640 women & 800 men are estimated to die from the condition.

Therapy Insights

Treatment of ALL consists of various therapies such as chemotherapy, targeted therapy, radiation therapy, and stem cell transplant. Chemotherapy segment dominated the market in 2016 owing to factors such as its ability to destroy leukemia cells and prevent thriving & multiplication of cancerous cells that impede the progress of disease. All these factors are responsible for the increase in prescription rate of chemotherapy over the last two decades. In chemotherapy, single or combination drugs (chemotherapy regimen) are used for treating ALL. This therapy includes cytotoxic agents, antimetabolites, alkylating agents, and other plant derivatives. Moreover, stem cell transplant can be used together with chemotherapy, which helps healthcare practitioners induce chemotherapy infusions at high doses for effective treatment.

Targeted therapy is the fastest growing segment over the forecast period. This therapy offers benefits such as higher precision and efficiency of treatment with faster recovery in comparison to chemotherapy. Furthermore, increasing preference for targeted therapies for the treatment of this condition is the driving force of the market.

Type Insights

ALL is classified into three types-Philadelphia (Ph) chromosome, precursor B-ALL, and T-cell ALL. The Philadelphia (Ph) chromosome is further classified into Ph-positive ALL and Ph-negative ALL. The chances of acquiring this disease increase with age.The drugs used for treatment of ALL are usually tyrosine kinase inhibitors such as dasatinib (Sprycel), imatinib (Glivec), and nilotinib (Tasigna). The above-mentioned drug has multiple indication with acute lymphoblastic leukemia as one of them. Usually, the drug used to treat chronic myeloid leukemia exhibits the potential to treat acute lymphoblastic leukemia as well.

The precursor B-ALL segment dominated the market in 2016 owing to its high development rate in early stages and high incidence. This segment is also expected to witness the fastest growth during the forecast period due to increasing prevalence of this condition in adults. According to National Comprehensive Cancer Network (NCCN), B-cell ALL subtype starts in young cells that develops in bone marrow and eventually become mature B-cell (B-lymphocytes) leading to a condition known as Burkitt type ALL (mature B-ALL). It is the most commonly occurring subtype of ALL. Precursor B-cell ALL is further classified into BCR-ABL gene and mature B-cell (Burkitt type). It accounts for 4% of total ALL cases.

Regional Insights

North America dominated the market in 2016. Presence of key manufacturers in the U.S. and well-established healthcare infrastructure are some of the factors responsible for its large share. Moreover, the U.S. is anticipated to witness substantial growth due to the launch of the drug, besponsa (inotuzumab ozogamicin), in August 2017 and presence of strong pipeline drugs such as eryaspase (asparaginase), which is under phase II of clinical trials.

Asia Pacific is anticipated to witness the fastest growth with a lucrative CAGR of 10.8% during the forecast period owing to high unmet clinical needs, rising disposable income, availability of effective treatment, and rising awareness about early diagnosis in emerging countries, such as China and India.

Competitive Insights

Some of the key players are Erytech Pharma; Spectrum Pharmaceuticals, Inc.; Pfizer, Inc.; Sigma-Tau s.p.a.; and Genzyme Corporation. Manufacturers are in the process of identifying new indications of existing drugs by conducting extensive clinical trials and targeting untapped opportunities.

These key players are adopting strategies such as mergers & acquisitions and collaborations for development of new products. For instance,in June 2015, Celgene Corporation announced a collaboration with Juno Therapeutics with an aim of developing and commercializing unique immunotherapies for autoimmune diseases and cancer.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the acute lymphocytic leukemia therapeutics market on the basis of type, therapy, and region:

• Therapy Outlook (Revenue, USD Million; 2014 - 2025)

  • Chemotherapy

    • Hyper-CVAD

    • CALGB 8811 regimen

    • Linker regimen

    • Nucleoside Metabolic Inhibitors

    • Oncaspar

  • Targeted therapy

  • Radiation Therapy

  • Stem cell transplantation

• Type Outlook (Revenue, USD Million; 2014 - 2025)

  • Philadelphia chromosome

  • Precursor B-cell ALL

  • T-cell ALL

• Regional Outlook (Revenue, USD Million; 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

  • Asia Pacific

    • China

    • Japan

    • India

  • Latin America

    • Mexico

    • Brazil

  • MEA

    • South Africa